Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

@article{Dooley2011MycophenolateVA,
  title={Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.},
  author={Mary Anne Dooley and David R. W. Jayne and Ellen M Ginzler and David Alan Isenberg and Nancy J. Olsen and David Wofsy and Frank Eitner and Gerald B. Appel and Gabriel N. Contreras and Laura J Lisk and Neil B. Solomons},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 20},
  pages={
          1886-95
        }
}
BACKGROUND Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis. METHODS We carried out a 36-month, randomized, double-blind, double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per kilogram of body weight per day), plus placebo in each group, in patients who met response criteria during a 6-month induction trial. The… 

Figures and Tables from this paper

Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis
TLDR
The cumulative renal relapse rates in the MMF group and TAC group were similar to the renal relapse rate in the AZA group, and no significant difference in the incidence of severe adverse event was observed among the groups.
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up
TLDR
TAC is non-inferior to MMF, when combined with prednisolone, for induction therapy of active LN, and with azathioprine maintenance for 5 years, a non-significant trend of higher incidence of renal flares and renal function decline is observed with the TAC regimen.
Mycophenolate as Maintenance Therapy for Lupus Nephritis with Impaired Renal Function
TLDR
Mycophenolate is effective and safe as a maintenance therapy for LN both in patients with normal renal function and in those with renal impairment.
The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis
TLDR
Bortezomib combined with glucocorticoids reduces proteinuria, improves renal function and decreases anti-autoantibodies, with good tolerance and mild adverse events, thus representing an alternative therapy for refractory LN and warranting further study.
The Mycophenolate Mofetil Therapy in Corticoresistent Idiopathic Focal Segmental Glomerulosclerosis
TLDR
It was concluded that in resistant Nephrotic Syndrome by FSGS, MMF can favor stable remission, preserving renal function and hence being considered as an alternative therapy to calcineurin inhibitors, but with lower toxicity.
Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil
TLDR
Long-term outcomes in terms of patient and renal survival of LN patients treated with CYP and MMF induction are similar, and most deaths occurred during induction, and sepsis was the most common cause of death.
Efficacy of High-Dose Mycophenolate Mofetil in Multitarget Therapy for Lupus Nephritis: Two Consecutive Case Reports
TLDR
Increasing MMF dose while maintaining the steroid dose in MT may induce complete remission; this will minimize the use of steroids in Japanese patients with refractory LN in conventional MT.
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study.
TLDR
A post hoc subgroup analysis of patients with low estimated glomerular filtration rates from a large trial of MMF compared to cyclophosphamide in lupus nephritis did not detect a difference in the primary outcome of response, however, MMF may result in quicker recovery of kidney function compared with those treated with cycloph phosphamide.
Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis
TLDR
Long-term data confirmed non-inferiority of TAC to MMF as induction therapy of LN and may be suitable targets for induction/consolidation therapy.
Immunosuppressive treatment for proliferative lupus nephritis.
TLDR
The effects of all treatment strategies on death (all causes) and ESKD were uncertain and the benefits and harms of different immunosuppressive treatments in people with biopsy-proven lupus nephritis were evaluated.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
TLDR
In this 24-week randomized, open-label, noninferiority trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile.
Mycophenolate Mofetil versus Azathioprine in the Maintenance Therapy of Lupus Nephritis
TLDR
Both therapeutic approaches with MMF or AZA, in combination with corticosteroids, are effective as a maintenance therapy for lupus nephritis.
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
TLDR
Fewer renal flares were observed in patients receiving MMF but the difference did not reach statistical significance and over a 3-year period, 24 h proteinuria, serum creatinine, serum albumin, serum C3, haemoglobin and global disease activity scores improved similarly in both groups.
Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)
TLDR
The Phase III Aspreva Lupus Management Study (ALMS) may provide invaluable comparative data on the efficacy and safety of MMF as LN induction and maintenance therapy.
Induction and maintenance therapy in proliferative lupus nephritis.
TLDR
Modern immunosuppression today allows us to reduce the dosage of steroids and to avoid the prolonged use of cyclophosphamide, and these newer strategies may result in fewer adverse effects, better quality of life and better survival for patients with proliferative lupus nephritis.
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
TLDR
Mycophenolate mofetil is a suitable alternative to cyclophosphamide for the treatment of renal and nonrenal disease manifestations in patients with biopsy-proven lupus nephritis and showed that remission could also be induced in other systems.
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
TLDR
MMF and IVC have similar efficacy overall to short-term induction therapy for LN, however, race, ethnicity and geographical region may affect treatment response; more Black and Hispanic patients responded to MMF than IVC.
Lupus Nephritis: Induction Therapy
TLDR
There is accumulating evidence that the combined use of mycophenolate mofetil and corticosteroid presents an effective treatment for severe proliferative lupus nephritis in different ethnic groups, and is associated with much fewer adverse effects compared with cyclophosphamide-based regimens.
Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis
Background:  The aim of the present study was to evaluate the efficacy of mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
  • M. Ward
  • Medicine, Biology
    Archives of internal medicine
  • 2000
TLDR
The incidence of end-stage renal disease (ESRD) due to lupus nephritis increased steadily over the 14-year study period, despite the introduction of efficacious new treatment regimens for lupu nephitis during this time.
...
...